plerixafor

P2, N=100, Recruiting, Thomas Jefferson University | Not yet recruiting --> Recruiting

P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

To address this, we developed a TME-responsive nanoliposome for the co-delivery of the photosensitizer chlorin e6 (Ce6) and the immunomodulatory agent AMD3100...This profound antitumor effect was driven by a significant enhancement of dendritic cell (DC) maturation (31.1 %) and a 1.62-fold increase in tumor infiltration of CD8 + T cells, coupled with a 76.11 % reduction in MDSC accumulation. In conclusion, this multifunctional nanoliposome, which synergizes immunogenic PDT with targeted MDSC regulation, presents a highly effective strategy for colon cancer treatment and opens a new avenue for advanced photoimmunotherapy.

A previous study reported that inhibiting CXCR4 with AMD3100 induces tumor cell death and enhances the efficacy of the chemotherapeutic agent cisplatin. Treatment with AMD3100 leads to a marked reduction in the CD105+ vessels and impairs the maturation of tumor micro-vessels, explaining the cause of observed necrosis. Thus, CXCR4 serves as a promising biomarker in OSCC, and its inhibition with AMD3100 offers the therapeutic potential, particularly in cases with advanced pathological grades.

P1, N=30, Completed, University of Chicago | Active, not recruiting --> Completed | N=15 --> 30

Massage is associated with enhanced motor function and white matter restoration in cerebral palsy, potentially through mechanisms involving the SDF-1/CXCR4 axis, increased homing of BMSCs-Exo to the brain, and enhanced oligodendrocyte attachment.

Mobilization with G-CSF plus plerixafor is associated with higher CD34+ cell yields, faster hematologic and immune recovery, lower complication rates, and better QoL outcomes compared with G-CSF plus chemotherapy in lymphoma patients undergoing ASCT.

Patients on daratumumab induction regimen exhibited an increased use of plerixafor when compared to non-daratumumab induction regimen (p < 0.001). The addition of daratumumab in induction therapy of multiple myeloma did not affect stem cell yield but increased dependence on plerixafor during mobilization therapy.

Their study reveals that bortezomib, combined with either tetrathiomolybdate or AMD3100, synergistically kills breast cancer by downregulating expression of the proteasome subunit PSMB5. Crucially, the in vivo antitumor efficacy of these combinations is strictly dependent on an intact immune system, enabling cytotoxic CD8⁺ T cell responses. Although this study raises important mechanistic questions for future investigation, it significantly opens new avenues for expanding the therapeutic application of proteasome inhibitors in solid tumors.

Using a murine tumor model built with Lewis Lung Carcinoma cell line, we further validated our findings that a PD-1 blockade, as well as a CXCR4 antagonist AMD3100, inhibited EC population in tumors and their CXCL12 expression...Moreover, we predicted MYC to be the potential regulator through which PD-1 blockades affect ECs. Together, our results suggest that PD-1 blockades have an anti-angiogenic effect besides boosting T cell immunity, and the CXCL12/CXCR4 pathway is a potential target for enhancing the effectiveness of PD-1 blockades.

Preclinical studies indicated that the combination of the CXCR4 antagonist AMD3100 and the AKT inhibitor GSK690693 synergistically inhibits GBM cell progression. Our findings unveil a novel signaling axis between ECs and tumor cells that directly impacts the acquisition of stemness traits, suggesting that targeting this pathway could represent a promising therapeutic strategy against GBM.

Immune checkpoint inhibitors (ICIs) combined with anti-angiogenic agents manifest improved survival in advanced hepatocellular carcinoma (HCC), but responses remain heterogeneous. Its high expression denotes an immunosuppressive TME. Targeting the NQO1/CXCL12/Tregs axis with Plerixafor may restore sensitivity and improve outcomes.